Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
26.69
-0.12 (-0.45%)
At close: Sep 14, 2026, 4:00 PM EDT
26.71
+0.02 (0.07%)
After-hours: Sep 14, 2026, 4:04 PM EDT
LKFT Revenue
Lakefront Biotherapeutics NV had revenue of 13.66M EUR in the quarter ending June 30, 2026, a decrease of -81.44%. This brings the company's revenue in the last twelve months to 1.03B, up 227.88% year-over-year. In the year 2025, Lakefront Biotherapeutics NV had annual revenue of 1.17B with 268.41% growth.
Revenue (ttm)
1.03B EUR
Revenue Growth
+227.88%
P/S Ratio
1.55
Revenue / Employee
5,264,133 EUR
Employees
196
Market Cap
1.75B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.17B | 849.32M | 268.41% |
| Dec 31, 2024 | 316.42M | 29.43M | 10.25% |
| Dec 31, 2023 | 287.00M | 9.62M | 3.47% |
| Dec 31, 2022 | 277.38M | -3.08M | -1.10% |
| Dec 31, 2021 | 280.46M | -249.81M | -47.11% |
| Dec 31, 2020 | 530.26M | -355.54M | -40.14% |
| Dec 31, 2019 | 885.80M | 578.13M | 187.91% |
| Dec 31, 2018 | 307.67M | 151.75M | 97.33% |
| Dec 31, 2017 | 155.92M | 4.31M | 2.84% |
| Dec 31, 2016 | 151.61M | 91.03M | 150.27% |
| Dec 31, 2015 | 60.58M | -29.44M | -32.70% |
| Dec 31, 2014 | 90.02M | -6.55M | -6.78% |
| Dec 31, 2013 | 96.57M | 4.35M | 4.71% |
| Dec 31, 2012 | 92.23M | -23.06M | -20.01% |
| Dec 31, 2011 | 115.29M | -21.27M | -15.57% |
| Dec 31, 2010 | 136.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immunocore Holdings | 430.78M |
| Vir Biotechnology | 303.23M |
| Maravai LifeSciences Holdings | 208.78M |
| Xencor | 104.97M |
| Septerna | 98.88M |
| Recursion Pharmaceuticals | 54.86M |
LKFT News
- 6 days ago - Acquisition of Own Shares - GlobeNewsWire
- 6 days ago - Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 13 days ago - Acquisition of Own Shares - GlobeNewsWire
- 21 days ago - Lakefront Biotherapeutics granted orphan drug designation for gamgertamig - TheFly
- 21 days ago - U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus - GlobeNewsWire
- 21 days ago - Lakefront Receives Transparency Notification from Bank of America - GlobeNewsWire
- 4 weeks ago - Lakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley - TheFly
- 4 weeks ago - Lakefront Biotherapeutics NV Earnings release: Q2 2026 - Filings